Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Cognition Therapeutics Inc’s stock clocked out at $2.43, down -2.02% from its previous closing price of $2.48. In other words, the price has decreased by -$2.02 from its previous closing price. On the day, 5.31 million shares were traded. CGTX stock price reached its highest trading level at $2.59 during the session, while it also had its lowest trading level at $2.28.
Ratios:
To gain a deeper understanding of CGTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.54 and its Current Ratio is at 1.54. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 19, 2024, Upgraded its rating to Buy and sets its target price to $1.50 from $1 previously.
On November 03, 2021, Oppenheimer started tracking the stock assigning an Outperform rating and target price of $22.Oppenheimer initiated its Outperform rating on November 03, 2021, with a $22 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 31 ’25 when Ricciardi Lisa bought 38,851 shares for $0.77 per share. The transaction valued at 30,001 led to the insider holds 38,851 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGTX now has a Market Capitalization of 178537456 and an Enterprise Value of 168262448.
Stock Price History:
The Beta on a monthly basis for CGTX is 1.55, which has changed by 2.8328075 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, CGTX has reached a high of $3.83, while it has fallen to a 52-week low of $0.22. The 50-Day Moving Average of the stock is 141.21%, while the 200-Day Moving Average is calculated to be 297.20%.
Shares Statistics:
It appears that CGTX traded 10.67M shares on average per day over the past three months and 11277340 shares per day over the past ten days. A total of 64.96M shares are outstanding, with a floating share count of 59.05M. Insiders hold about 19.63% of the company’s shares, while institutions hold 7.17% stake in the company. Shares short for CGTX as of 1755216000 were 6226969 with a Short Ratio of 0.58, compared to 1752537600 on 7414526. Therefore, it implies a Short% of Shares Outstanding of 6226969 and a Short% of Float of 9.2700005.
Earnings Estimates
The current assessment of Cognition Therapeutics Inc (CGTX) involves the perspectives of 4.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.05 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.33 and -$0.51 for the fiscal current year, implying an average EPS of -$0.42. EPS for the following year is -$0.28, with 3.0 analysts recommending between -$0.15 and -$0.37.
